» Articles » PMID: 28664936

PD-L1 Immunohistochemistry in Clinical Diagnostics of Lung Cancer: Inter-pathologist Variability is Higher Than Assay Variability

Overview
Journal Mod Pathol
Specialty Pathology
Date 2017 Jul 1
PMID 28664936
Citations 88
Authors
Affiliations
Soon will be listed here.
Abstract

Assessment of programmed cell death ligand 1 (PD-L1) immunohistochemical staining is used for decision on treatment with programmed cell death 1 and PD-L1 checkpoint inhibitors in lung adenocarcinomas and squamous cell carcinomas. This study aimed to compare the staining properties of tumor cells between the antibody clones 28-8, 22C3, SP142, and SP263 and investigate interrater variation between pathologists to see if these stainings can be safely evaluated in the clinical setting. Using consecutive sections from a tissue microarray with tumor tissue from 55 resected lung cancer cases, staining with five PD-L1 assays (28-8 from two different vendors, 22C3, SP142, and SP263) was performed. Seven pathologists individually evaluated the percentage of positive tumor cells, scoring each sample applying cutoff levels used in clinical studies: <1% positive tumor cells (score 0), 1-4% (score 1), 5-9% (score 2), 10-24% (score 3), 25-49% (score 4), and >50% positive tumor cells (score 5). Pairwise analysis of antibody clones showed weighted kappa values in the range of 0.45-0.91 with the highest values for comparisons with 22C3 and 28-8 and the lowest involving SP142. Excluding SP142 resulted in kappa 0.75-0.91. Weighted kappa for interobserver variation between pathologists was 0.71-0.96. Up to 20% of the cases were differently classified as positive or negative by any pathologist compared with consensus score using ≥1% positive tumor cells as cutoff. A significantly better agreement between pathologists was seen using ≥50% as cutoff (0-5% of cases). In conclusion, the concordance between the PD-L1 antibodies 22C3, 28-8 and SP263 is relatively good when evaluating lung cancers and suggests that any one of these assays may be sufficient as basis for decision on treatment with nivolumab, pembrolizumab, and durvalumab. The scoring of the pathologist presents an intrinsic source of error that should be considered especially at low PD-L1 scores.

Citing Articles

Current Biomarkers in Non-Small Cell Lung Cancer-The Molecular Pathologist's Perspective.

Steinestel K, Arndt A Diagnostics (Basel). 2025; 15(5).

PMID: 40075878 PMC: 11899415. DOI: 10.3390/diagnostics15050631.


LAG-3 and TIM-3 expression in melanoma and histopathological correlation: a single-center study.

Aygun M, Yalcin O Clin Transl Oncol. 2025; .

PMID: 39752003 DOI: 10.1007/s12094-024-03836-3.


A universal immunohistochemistry analyzer for generalizing AI-driven assessment of immunohistochemistry across immunostains and cancer types.

Brattoli B, Mostafavi M, Lee T, Jung W, Ryu J, Park S NPJ Precis Oncol. 2024; 8(1):277.

PMID: 39627299 PMC: 11615360. DOI: 10.1038/s41698-024-00770-z.


Development of Ex Vivo Analysis for Examining Cell Composition, Immunological Landscape, Tumor and Immune Related Markers in Non-Small-Cell Lung Cancer.

Ufimtseva E, Gileva M, Kostenko R, Kozlov V, Gulyaeva L Cancers (Basel). 2024; 16(16).

PMID: 39199657 PMC: 11352364. DOI: 10.3390/cancers16162886.


A clinical-radiomic-pathomic model for prognosis prediction in patients with hepatocellular carcinoma after radical resection.

Xie Q, Zhao Z, Yang Y, Wang X, Wu W, Jiang H Cancer Med. 2024; 13(11):e7374.

PMID: 38864473 PMC: 11167608. DOI: 10.1002/cam4.7374.


References
1.
Borghaei H, Paz-Ares L, Horn L, Spigel D, Steins M, Ready N . Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373(17):1627-39. PMC: 5705936. DOI: 10.1056/NEJMoa1507643. View

2.
Herbst R, Soria J, Kowanetz M, Fine G, Hamid O, Gordon M . Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014; 515(7528):563-7. PMC: 4836193. DOI: 10.1038/nature14011. View

3.
Mattsson J, Brunnstrom H, Jabs V, Edlund K, Jirstrom K, Mindus S . Inconsistent results in the analysis of ALK rearrangements in non-small cell lung cancer. BMC Cancer. 2016; 16:603. PMC: 4974795. DOI: 10.1186/s12885-016-2646-x. View

4.
Gettinger S, Horn L, Gandhi L, Spigel D, Antonia S, Rizvi N . Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2015; 33(18):2004-12. PMC: 4672027. DOI: 10.1200/JCO.2014.58.3708. View

5.
Micke P, Mattsson J, Djureinovic D, Nodin B, Jirstrom K, Tran L . The Impact of the Fourth Edition of the WHO Classification of Lung Tumours on Histological Classification of Resected Pulmonary NSCCs. J Thorac Oncol. 2016; 11(6):862-72. DOI: 10.1016/j.jtho.2016.01.020. View